Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
42.98
-1.92 (-4.28%)
At close: Apr 28, 2026, 4:00 PM EDT
43.27
+0.29 (0.67%)
Pre-market: Apr 29, 2026, 7:05 AM EDT
Company Description
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
The company was founded in 2019 and is headquartered in Boulder, Colorado.
Enliven Therapeutics, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Mar 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 60 |
| CEO | Richard Fair |
Contact Details
Address: 6200 Lookout Road Boulder, Colorado 80301 United States | |
| Phone | 720 647 8519 |
| Website | enliventherapeutics.com |
Stock Details
| Ticker Symbol | ELVN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001672619 |
| CUSIP Number | 29337E102 |
| ISIN Number | US29337E1029 |
| Employer ID | 81-1523849 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard A. Fair | Chief Executive Officer, President and Director |
| Samuel S. Kintz M.B.A. | Co-Founder and Head of Pipeline |
| Dr. Joseph P. Lyssikatos Ph.D. | Co-Founder and Chief Scientific Officer |
| Dr. Helen Louise Collins M.D. | Chief Medical Officer |
| Anish Patel Pharm.D. | Co-Founder and Chief Operating Officer |
| Benjamin Hohl | Chief Financial Officer and Head of Corporate Development |
| Dr. Galya D. Blachman Esq., Ph.D. | Chief Legal Officer and Head of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | ARS | Filing |
| Apr 27, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 27, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 15, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 31, 2026 | 144 | Filing |
| Mar 31, 2026 | 144 | Filing |
| Mar 25, 2026 | 144 | Filing |
| Mar 24, 2026 | 144 | Filing |
| Mar 9, 2026 | 144 | Filing |
| Mar 6, 2026 | 144 | Filing |